40% of epilepsy cases are genetic. Current treatments only address the symptoms, rather than treating the underlying biological mechanisms. This is in part due to the fact that genetic approaches to the study of epilepsy have not been able to sufficiently deal with its complexities.
There are different types of epilepsy and multiple causative genes. This often hinders its diagnosis, making it necessary in the majority of cases to adopt a more global diagnostic approach using sequencing panels.
One of the many panels offered is a global NGS panel for epilepsy covering all the genes known to be involved in this process to date.
The coverage is 100% and the average coverage depth greater than 300X, with a minimum of 50X, making this the panel with the highest diagnostic capacity.
ICM provides diagnostic solutions for the variety of different cases that clinicians may be presented with during consultations, helping specialists to choose which study to perform. Contact the advisory team by email at email@example.com. ICM offers clinicians a wide range of genetic studies that can be viewed in the available catalogue.